CLINICAL TRIALS

DATTEP (Phase III)

Investigator physician: Dr Lucie HOPES

Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor

Parkinson et Tremblement Essentiel


Multi-center, non-inferiority, randomized, cross-over, single-blind (expert panel) Phase III interventional study.
Recruitment was carried out by neurologists experienced in neurology departments: 56 parkinsonian patients and 56 patients with essential tremor whose diagnosis was based on international recommendations.
Each patient underwent a SPECT/CT examination with Ioflupane 123I-FP-CIT and a PET/CT examination with 18F-LBT-999 one week apart in the nuclear medicine departments.
The order in which these two examinations were performed was randomized.


Imaging: PET/CT 18F-LBT-999 (produit à l'étude) versus [123I]-FP-CIT en SPECT/CT
Study status: Recruiting
Clinical Trial number: NCT04265209
Funding:

Zionexa